These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

772 related items for PubMed ID: 23357969

  • 1. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
    Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F.
    Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
    [Abstract] [Full Text] [Related]

  • 2. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [Abstract] [Full Text] [Related]

  • 4. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A, Katakami N, Fujita S, Kaji R, Imai Y, Takahashi Y, Nishimura T, Tomii K, Ishihara K.
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [Abstract] [Full Text] [Related]

  • 5. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [Abstract] [Full Text] [Related]

  • 6. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.
    Cancer; 2012 Feb 01; 118(3):729-39. PubMed ID: 21720997
    [Abstract] [Full Text] [Related]

  • 7. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakayama E, Takahashi T, Menju T, Takenaka K, Miyahara R, Huang CL, Okubo K, Bando T, Date H.
    Ann Surg Oncol; 2012 Jul 01; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [Abstract] [Full Text] [Related]

  • 8. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan.
    Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YT, Chen YR, Huang SF.
    J Thorac Oncol; 2010 Aug 01; 5(8):1175-84. PubMed ID: 20559151
    [Abstract] [Full Text] [Related]

  • 9. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.
    J Thorac Oncol; 2011 Jun 01; 6(6):1006-15. PubMed ID: 21532509
    [Abstract] [Full Text] [Related]

  • 10. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.
    Anticancer Res; 2013 Apr 01; 33(4):1705-11. PubMed ID: 23564819
    [Abstract] [Full Text] [Related]

  • 11. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
    Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L.
    Cancer Chemother Pharmacol; 2012 May 01; 69(5):1289-99. PubMed ID: 22302407
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.
    Clin Lung Cancer; 2014 Jan 01; 15(1):86-92. PubMed ID: 24139827
    [Abstract] [Full Text] [Related]

  • 13. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
    Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L.
    Lung Cancer; 2012 Oct 01; 78(1):81-6. PubMed ID: 22770374
    [Abstract] [Full Text] [Related]

  • 14. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wannesson L, Antonelli P, Balzarini P, Sessa F, Mazzucchelli L, Tibiletti MG, Martin V.
    Clin Lung Cancer; 2016 Jan 01; 17(1):56-61. PubMed ID: 26381283
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 01; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 16. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.
    J Thorac Oncol; 2009 Jan 01; 4(1):22-9. PubMed ID: 19096302
    [Abstract] [Full Text] [Related]

  • 17. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.
    Cancer Genet; 2013 Jan 01; 206(1-2):26-31. PubMed ID: 23313110
    [Abstract] [Full Text] [Related]

  • 18. Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers.
    Wei H, Lu W, Li M, Zhang Q, Lu S.
    Yonsei Med J; 2016 Jan 01; 57(1):50-7. PubMed ID: 26632382
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.
    J Thorac Oncol; 2008 Dec 01; 3(12):1446-53. PubMed ID: 19057271
    [Abstract] [Full Text] [Related]

  • 20. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
    Takeda M, Okamoto I, Fujita Y, Arao T, Ito H, Fukuoka M, Nishio K, Nakagawa K.
    J Thorac Oncol; 2010 Mar 01; 5(3):399-400. PubMed ID: 20186026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.